LEADER 01120nam0-22003491i-450- 001 990005525760203316 005 20050705120000.0 035 $a000552576 035 $aUSA01000552576 035 $a(ALEPH)000552576USA01 035 $a000552576 100 $a20050705d1975-------|0enac50------ba 101 $aeng 102 $aIT 105 $a|||| ||||| 200 1 $aBritish economic thought and India$e1600-1858$ea study in the history of development economics$fby William J. Barber - Oxford : Clarendon Press, 1975 - viii, 243 p$g23 cm 606 $aEconomia$2FI 620 $dOxford 676 $a330.0941$cEconomia. Gran Bretagna.$v21 700 1$aBARBER,$bWilliam Joseph$0490077 712 $aClarendon Press 801 $aIT$bSOL$c20120104 912 $a990005525760203316 950 $aDIP.TO SCIENZE ECONOMICHE - (SA)$dDS 300 330.0941 BAR$e1219 DISES 951 $a300 330.0941 BAR$b1219 DISES 959 $aBK 969 $aDISES 979 $c20121027$lUSA01$h1532 979 $c20121027$lUSA01$h1613 996 $aBritish economic thought and India$91130485 997 $aUNISA NUM $aUSA14258 LEADER 00906nam a2200265 i 4500 001 991000605259707536 005 20020503191909.0 008 940524s1980 us ||| | eng 020 $a0852261586 035 $ab10102334-39ule_inst 035 $aLE02519032$9ExL 040 $aFac. Economia$bita 082 0 $a519.5 100 1 $aSinha, S. K$079753 245 10$aLife testing and reliability estimation /$cS.K. Sinha, B.K. Kale 260 $aNew Delhi :$bWiley Eastern,$cc1980 300 $avi, 196 p. ;$c20 cm 650 4$aStatistica 700 1 $aKale, B. K. 907 $a.b10102334$b08-02-16$c27-06-02 912 $a991000605259707536 945 $aLE025 ECO 519.5 SIN01.01$g1$i2025000020207$lle025$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10119280$z27-06-02 996 $aLife testing and reliability estimation$9197244 997 $aUNISALENTO 998 $ale025$b01-01-94$cm$da $e-$feng$gus $h0$i1 LEADER 05323nam 22006494a 450 001 9910830389603321 005 20170919210923.0 010 $a1-282-35017-X 010 $a9786612350177 010 $a0-470-98579-8 010 $a0-470-98578-X 035 $a(CKB)1000000000687511 035 $a(EBL)470159 035 $a(SSID)ssj0000312772 035 $a(PQKBManifestationID)11223169 035 $a(PQKBTitleCode)TC0000312772 035 $a(PQKBWorkID)10332302 035 $a(PQKB)10941282 035 $a(MiAaPQ)EBC470159 035 $a(OCoLC)264621207 035 $a(PPN)199221944 035 $a(EXLCZ)991000000000687511 100 $a20071207d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aViral therapy of cancer$b[electronic resource] /$feditors, Kevin J. Harrington, Richard G. Vile, Hardev S. Pandha 210 $aChichester, England ;$aHoboken, NJ $cJohn Wiley & Sons$dc2008 215 $a1 online resource (426 p.) 300 $aDescription based upon print version of record. 311 $a0-470-01922-0 320 $aIncludes bibliographical references and index. 327 $aViral Therapy of Cancer; Contents; Foreword; Preface; Contributors; 1 Adenoviruses; 1.1 Introduction; 1.2 Viral structure and life cycle; 1.3 Adenoviral vectors; 1.4 Targeting adenoviral vectors; 1.5 Clinical applications of adenoviral gene therapy; 1.6 Adenoviral vectors for immunotherapy; 1.7 Adenoviral vectors for suicide gene therapy; 1.8 Adenoviral vectors for gene replacement therapy; 1.9 Oncolytic adenoviral therapy; 1.10 Adverse outcomes of adenoviral gene therapy; 1.11 Summary; References; 2 Application of HSV-1 vectors to the treatment of cancer; 2.1 Introduction 327 $a2.2 Basic biology of HSV2.3 Replication competent or oncolytic vectors; 2.4 Replication defective vectors; 2.5 Amplicons; 2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy; 2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy; 2.8 Summary and conclusions; Acknowledgements; References; 3 Adeno-associated virus; 3.1 Introduction; 3.2 Biology and life cycle of AAV; 3.3 AAV serotypes; 3.4 Production of recombinant AAV; 3.5 Gene therapy for cancer treatment; 3.6 Anti-oncogenic properties of AAV 327 $a3.7 Molecular chemotherapy studies with rAAV3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy; 3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses; 3.10 rAAV vectors can be used to initiate immune responses; 3.11 Altering AAV tropism for tumour-specific delivery; 3.12 Clinical trials involving rAAV; 3.13 Conclusion; Acknowledgements; References; 4 Retroviruses; 4.1 Introduction; 4.2 Structure of retroviral particles; 4.3 Retroviral genome; 4.4 Retroviral life cycle; 4.5 Retroviral vectors 327 $a4.6 Safety of retroviral vectors: insertional mutagenesis4.7 Gene therapy of X-linked SCID; 4.8 Retroviral cancer gene therapy; 4.9 Immunomodulatory approaches; 4.10 Conclusions; References; 5 Lentiviral vectors for cancer gene therapy; 5.1 Development of lentiviral vectors (LV); 5.2 Targeting of transgene expression; 5.3 Host immune responses to LV and their transgene; 5.4 Transgenesis; 5.5 Haematopoietic stem cell gene transfer; 5.6 Cancer treatment by LV; 5.7 Approved clinical trials using LV; 5.8 Conclusions; References; 6 Poxviruses as immunomodulatory cancer therapeutics 327 $a6.1 Introduction6.2 General features of poxvirus structure and biology; 6.3 Clinically applicable poxviruses; 6.4 Poxviruses as potential cancer therapeutics; 6.5 Clinical experience with poxviruses; 6.6 Conclusions; References; 7 Oncolytic herpes simplex viruses; 7.1 Introduction; 7.2 Herpes simplex virology; 7.3 Properties of HSV relevant to oncolytic virus therapy; 7.4 Mutations giving tumour-selective replication; 7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG); 7.6 Prodrug activation therapy and oncolytic HSV 327 $a7.7 Combination of oncolytic HSV with immunomodulatory gene expression 330 $aIn the last decade there has been an explosion of interest in viral therapies for cancer. Viral agents have been developed that are harmless to normal tissues but selectively able to kill cancer cells. These agents have been endowed with additional selectivity and potency through genetic manipulation. Increasingly these viruses are undergoing evaluation in clinical trials, both as single agents and in combination with standard chemotherapy and radiotherapy. This book provides a comprehensive yet succinct overview of the current status of viral therapy of cancer. Chapters coherently present 606 $aViruses$xTherapeutic use 606 $aCancer$xTreatment 615 0$aViruses$xTherapeutic use. 615 0$aCancer$xTreatment. 676 $a616.99/406 676 $a616.99406 701 $aHarrington$b Kevin J.$f1958-$038288 701 $aPandha$b Hardev$01680950 701 $aVile$b Richard G$078071 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830389603321 996 $aViral therapy of cancer$94050015 997 $aUNINA